Literature DB >> 15589814

Tetrahydrobiopterin responsiveness in patients with phenylketonuria.

Belén Pérez-Dueñas1, Maria Antonia Vilaseca, Anna Mas, Nilo Lambruschini, Rafael Artuch, Lilian Gómez, Julia Pineda, Alejandra Gutiérrez, Montse Mila, Jaume Campistol.   

Abstract

OBJECTIVES: To investigate the BH4 response in a group of patients with phenylketonuria (PKU) in order to offer this alternative treatment to the responsive patients. DESIGN AND METHODS: The 24-h-long Phe/BH4 loading test was performed on 64 PKU patients requiring dietary treatment.
RESULTS: All patients with mild-PKU and 75% of patients with moderate-PKU were BH4 responsive, while only 11% of classic-PKU patients showed good/partial response (P < 0.0001). The percentages of Phe decrease after the BH4 loading test were significantly different in the three PKU phenotypes (mild PKU: 67.9 +/- 18.7; moderate PKU: 37.4 +/- 16.8; and classical PKU: 21.9 +/- 13.7; ANOVA with Bonferroni correction: P < 0.0001). We report four mutations (P147S, D222G, P275S, and P362T) not previously associated with BH4 responsiveness, all of them combined with mutations with zero predicted residual activity.
CONCLUSION: Both the percentage of Phe decrease and the Phe value achieved 24 h after BH4 loading are valuable data in predicting a response. We report four mutations not previously associated with BH4 responsiveness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15589814     DOI: 10.1016/j.clinbiochem.2004.09.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  11 in total

1.  Platelet serotonin concentrations in PKU patients under dietary control and tetrahydrobiopterin treatment.

Authors:  A Ormazabal; M A Vilaseca; B Pérez-Dueñas; N Lambruschini; L Gómez; J Campistol; R Artuch
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Connecting mutant phenylalanine hydroxylase with phenylketonuria.

Authors:  Shaomin Yan; Guang Wu
Journal:  J Clin Monit Comput       Date:  2008-09-05       Impact factor: 2.502

3.  Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency.

Authors:  M R Zurflüh; L Fiori; B Fiege; I Ozen; M Demirkol; K H Gärtner; B Thöny; M Giovannini; N Blau
Journal:  J Inherit Metab Dis       Date:  2006-11-07       Impact factor: 4.982

4.  Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.

Authors:  F K Trefz; D Scheible; H Götz; G Frauendienst-Egger
Journal:  J Inherit Metab Dis       Date:  2008-10-30       Impact factor: 4.982

5.  Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control.

Authors:  M Lindner; G Gramer; S F Garbade; P Burgard
Journal:  J Inherit Metab Dis       Date:  2009-06-10       Impact factor: 4.982

6.  Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia.

Authors:  G Gramer; P Burgard; S F Garbade; M Lindner
Journal:  J Inherit Metab Dis       Date:  2007-08-06       Impact factor: 4.982

7.  Effect of BH(4) supplementation on phenylalanine tolerance.

Authors:  A Burlina; N Blau
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

Review 8.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

9.  Quality of Life (QoL) assessment in a cohort of patients with phenylketonuria.

Authors:  Chiara Cazzorla; Luca Cegolon; Alessandro P Burlina; Andrea Celato; Pamela Massa; Laura Giordano; Giulia Polo; Aurora Daniele; Francesco Salvatore; Alberto B Burlina
Journal:  BMC Public Health       Date:  2014-12-04       Impact factor: 3.295

Review 10.  Cofactor engineering for enhancing the flux of metabolic pathways.

Authors:  M Kalim Akhtar; Patrik R Jones
Journal:  Front Bioeng Biotechnol       Date:  2014-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.